Tecvayli 30 mg (Teclistamab SOLUTION) 30 MG

TECVAYLI 30 MG is a subcutaneous solution containing teclistamab, used for targeted therapy. This medication is designed to support specific treatment protocols as prescribed by healthcare professionals.

Strength

30 MG

Manufacturer / TM Owner

JANSSEN INC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

TECVAYLI 30 MG is primarily used in the management of certain hematological conditions. Teclistamab, the active ingredient, is a bispecific antibody that targets specific proteins involved in cancer cell growth. This solution is administered subcutaneously and is intended for use under medical supervision to support treatment plans for eligible patients.

Side Effects

Common effects of TECVAYLI 30 MG may include reactions at the injection site, such as redness or swelling. Some individuals might experience systemic effects like fatigue or fever. These effects vary among users and should be discussed with a healthcare provider.

Precautions & Warnings

TECVAYLI 30 MG should be handled with care, ensuring proper storage and administration techniques. It is essential to follow healthcare provider instructions regarding dosage and administration. Patients should be monitored for any adverse reactions and report them promptly.

Avoid Interactions

TECVAYLI 30 MG may interact with other medications, particularly those that affect the immune system. It is important to inform healthcare providers about all current medications to avoid potential interactions. Alcohol and certain supplements might also influence the effectiveness or safety of this treatment.

Frequently Asked Questions

TECVAYLI 30 MG is used in the treatment of certain hematological conditions, targeting specific proteins involved in cancer cell growth.

TECVAYLI 30 MG is administered subcutaneously, typically under the guidance of a healthcare professional.

Common effects may include injection site reactions, fatigue, and fever. These effects vary among individuals.

Potential interactions with other medications should be discussed with a healthcare provider to ensure safety and effectiveness.

Proper storage, administration techniques, and monitoring for adverse reactions are essential precautions when using TECVAYLI 30 MG.

Editorial & Trust Signals

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical wholesaler & exporter

Last updated: 17 Jun 2026

References

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.